I initiated coverage on Senesco (SNTI) four months ago when it was trading at $3. Shares rose above $7, but have since retreated. This provides an ideal opportunity for investors because since my last article, 2 positive events have occurred:
Number 1: Senesco just reported excellent data for cohort 3 of the current clinical trial. This milestone event takes Senesco one step closer to addressing the $75 billion cancer drug market.
Number 2: Opko's (NYSEMKT:OPK), Dr. Phillip Frost just initiated a 9.99% position in Senesco. As some of my readers know, all my Dr. Frost investments have provided returns above 100%. For example, soon after Dr. Frost initiated a position in MusclePharm (OTCQB:MSLP), the stock went...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|